Business Description
ISIN : US4050241003
Share Class Description:
HAE: Ordinary SharesTotal Employee Number:
3,009Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 1.4 | |||||
Debt-to-EBITDA | 4.34 | |||||
Interest Coverage | 8.17 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.09 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.4 | |||||
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 51.3 | |||||
3-Year Book Growth Rate | 2.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.72 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.45 | |||||
9-Day RSI | 59.32 | |||||
14-Day RSI | 65.01 | |||||
3-1 Month Momentum % | 17.31 | |||||
6-1 Month Momentum % | 36.97 | |||||
12-1 Month Momentum % | 62.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.08 | |||||
Quick Ratio | 1.91 | |||||
Cash Ratio | 0.85 | |||||
Days Inventory | 214.97 | |||||
Days Sales Outstanding | 55.96 | |||||
Days Payable | 34.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.6 | |||||
Shareholder Yield % | 0.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.03 | |||||
Operating Margin % | 18.05 | |||||
Net Margin % | 7.12 | |||||
EBITDA Margin % | 20 | |||||
FCF Margin % | 21.54 | |||||
OCF Margin % | 24.27 | |||||
ROE % | 11.26 | |||||
ROA % | 3.96 | |||||
ROIC % | 8.81 | |||||
3-Year ROIIC % | 11.08 | |||||
ROC (Joel Greenblatt) % | 24.86 | |||||
ROCE % | 8.02 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 49.7 | |||||
Forward PE Ratio | 19.13 | |||||
PE Ratio without NRI | 20.24 | |||||
Shiller PE Ratio | 55.1 | |||||
Price-to-Owner-Earnings | 28.67 | |||||
PEG Ratio | 1.46 | |||||
PS Ratio | 3.49 | |||||
PB Ratio | 5.51 | |||||
Price-to-Free-Cash-Flow | 16.3 | |||||
Price-to-Operating-Cash-Flow | 14.47 | |||||
EV-to-EBIT | 34.7 | |||||
EV-to-Forward-EBIT | 20.83 | |||||
EV-to-EBITDA | 20.58 | |||||
EV-to-Revenue | 4.11 | |||||
EV-to-Forward-Revenue | 4.02 | |||||
EV-to-FCF | 19.1 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 1.77 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.1 | |||||
Earnings Yield (Greenblatt) % | 2.88 | |||||
FCF Yield % | 6.31 | |||||
Forward Rate of Return (Yacktman) % | 21.28 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:HAE
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Haemonetics Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,352.013 | ||
| EPS (TTM) ($) | 2.04 | ||
| Beta | 0.498 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.44 | ||
| Volatility % | 72.48 | ||
| 14-Day RSI | 65.01 | ||
| 14-Day ATR ($) | 2.928435 | ||
| 20-Day SMA ($) | 101.446 | ||
| 12-1 Month Momentum % | 62.37 | ||
| 52-Week Range ($) | 47.315 - 109.5707 | ||
| Shares Outstanding (Mil) | 45.5 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Haemonetics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Haemonetics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-05 08:00 | In 150 days | ||
| Third quarter earnings results for 2027 | 2027-02-05 06:00 | In 150 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-06 08:00 | In 59 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 06:00 | In 59 days | ||
| First quarter earnings conference call for 2027 | 2026-08-06 08:00 | 83.60 (-2.81%) | ||
| First quarter earnings results for 2027 | 2026-08-06 06:00 | 83.60 (-2.81%) | ||
| General meeting for 2026 | 2026-07-24 08:00 | 77.40 (-0.32%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 16:00 | 71.28 (+1.68%) | ||
| Annual report for 2026 | 2026-05-20 | 56.85 (-1.51%) | ||
| Guidance call for 2026 | 2026-05-12 08:00 | 52.24 (-4.41%) |
Haemonetics Corp Frequently Asked Questions
Guru Commentaries on NYSE:HAE
We initiated a position in Haemonetics Corporation (HAE), a developer and distributor of a broad portfolio of hematology products and solutions. The company operates across three primary segments: Plasma, Blood Center, and Hospital. With management’s continued emphasis on life-sustaining healthcare applications, we believe Haemonetics stands to benefit from favorable demographic trends, rising demand for plasma-based therapies, and continued innovation in critical care technologies.
Haemonetics is a global provider of hematology and blood management products and solutions. Despite a year-over-year revenue decline tied to planned portfolio transitions, the company’s shares beat analyst expectations. The market reaction was overly pessimistic, overshadowing solid underlying demand and margin expansion. We believe that the company’s strong competitive position within the plasmapheresis market, along with increased investment in research and development, should create value for shareholders over a multi-year period.
Haemonetics (HAE) is a global provider of hematology and blood management products and solutions. The company delivered mixed results during the quarter, beating analyst earnings estimates but posting weaker than expected revenue results. We believe that the company’s strong competitive position within the plasmapheresis market along with increased investment in research and development should create value for shareholders over a multi-year period.
Haemonetics is a global provider of hematology and blood management products and solutions. The company delivered mixed results during the quarter, beating analyst earnings estimates but posting weaker than expected revenue results. We believe the company’s strong competitive position within the plasmapheresis market along with increased investment in research and development should create value for shareholders over a multi-year period.
Press Release
Articles on Haemonetics Corp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
